The fireside chat will be broadcast live and archived on the Company's website at www.ibioinc.com under "News & Events" in the Investors section.
About
iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming System® combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s subsidiary, iBio
Contact:
Investor Relations
(646) 274-3580
skilmer@ibioinc.com
Source:
2021 GlobeNewswire, Inc., source